Stockreport

How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, mirroring its existing U.S. indication. This first authorization for ANKTIVA in [Read more]